Table 1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
收藏数据链接：
官方服务：
资源简介：
Demographics, baseline characteristics, and prior treatments—safety analysis set (N = 151).
创建时间：
2025-07-15
